Cohort studies of patients with advanced cancers treated with PD-1 or PD-L1 inhibitors have similarly indicated that the presence of mature TLSs-identified by CD3, CD20, and CD23 expression via IHC-predicts favorable immunotherapeutic outcomes [281]. The gene discussed is PDCD1; the disease is cancer.